← Back to Screener
The Oncology Institute, Inc. Common Stock (TOI)
Price$4.78
Value ScoreD
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)28.82%
Price vs S&P 500 (4W)10.83%
VGM Score66.80
Market Capitalization$468.92M
All Metrics
Book Value / Share (Quarterly)$0.06
P/TBV (Annual)3.85x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)25.80%
Cash Flow / Share (Quarterly)$-0.26
Price vs S&P 500 (YTD)20.81%
Gross Margin (TTM)15.12%
Net Profit Margin (TTM)-7.97%
EPS (TTM)$-0.45
10-Day Avg Trading Volume1.62M
EPS Excl Extra (TTM)$-0.45
Revenue Growth (5Y)21.81%
EPS (Annual)$-0.66
ROI (Annual)-66.86%
Gross Margin (Annual)15.20%
Net Profit Margin (5Y Avg)-11.88%
Cash / Share (Quarterly)$0.30
Revenue Growth QoQ (YoY)41.22%
ROA (Last FY)-36.81%
Revenue Growth TTM (YoY)35.37%
EBITD / Share (TTM)$-0.26
ROE (5Y Avg)-401.71%
Operating Margin (TTM)-5.99%
Cash Flow / Share (Annual)$-0.28
P/B Ratio92.51x
P/B Ratio (Quarterly)20.00x
Net Income / Employee (Annual)$-94,500
EV / Revenue (TTM)0.95x
Net Interest Coverage (TTM)-4.27x
ROA (TTM)-26.52%
EV / EBITDA (TTM)60.39x
EPS Incl Extra (Annual)$-0.66
Current Ratio (Annual)1.59x
Quick Ratio (Quarterly)1.13x
3-Month Avg Trading Volume1.83M
52-Week Price Return46.11%
Revenue / Employee (TTM)$851,400
Tangible BV / Share (Quarterly)$0.17
P/S Ratio (Annual)0.93x
Asset Turnover (Annual)3.05x
52-Week High$4.88
Operating Margin (5Y Avg)-19.75%
EPS Excl Extra (Annual)$-0.66
CapEx CAGR (5Y)21.88%
26-Week Price Return44.75%
Quick Ratio (Annual)1.31x
13-Week Price Return57.38%
Total Debt / Equity (Annual)25.95x
Current Ratio (Quarterly)1.47x
Enterprise Value$517.25M
Revenue / Share Growth (5Y)16.71%
Asset Turnover (TTM)3.33x
Revenue / Employee (Annual)$784,300
Inventory Turnover (Annual)31.68x
Pretax Margin (Annual)-12.08%
Cash / Share (Annual)$0.34
3-Month Return Std Dev70.32%
Gross Margin (5Y Avg)17.61%
Net Income / Employee (TTM)$-67,900
EBITDA Interim CAGR (5Y)54.84%
ROE (Last FY)-1801.70%
Net Interest Coverage (Annual)-4.69x
EPS Basic Excl Extra (Annual)$-0.66
P/FCF (TTM)215.79x
Receivables Turnover (TTM)10.16x
Total Debt / Equity (Quarterly)14.58x
EPS Incl Extra (TTM)$-0.45
Receivables Turnover (Annual)9.37x
ROI (TTM)-64.06%
P/S Ratio (TTM)0.86x
Pretax Margin (5Y Avg)-11.98%
Revenue / Share (Annual)$5.44
Tangible BV / Share (Annual)$0.53
Price vs S&P 500 (52W)17.90%
Year-to-Date Return31.74%
5-Day Price Return2.18%
EPS Normalized (Annual)$-0.66
ROA (5Y Avg)-23.85%
Net Profit Margin (Annual)-12.06%
Month-to-Date Return21.50%
Cash Flow / Share (TTM)$-0.95
EBITD / Share (Annual)$-0.32
Operating Margin (Annual)-7.18%
LT Debt / Equity (Annual)25.95x
ROI (5Y Avg)-34.14%
LT Debt / Equity (Quarterly)14.58x
EPS Basic Excl Extra (TTM)$-0.45
P/TBV (Quarterly)2.56x
P/B Ratio (Annual)6.51x
Inventory Turnover (TTM)25.32x
Pretax Margin (TTM)-8.00%
Book Value / Share (Annual)$0.05
Price vs S&P 500 (13W)47.64%
Beta0.35x
P/FCF (Annual)193.77x
Revenue / Share (TTM)$5.36
ROE (TTM)-482.58%
52-Week Low$2.02
vGradeD
gGradeA
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.02est. -0.08
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Physicians' Offices(10)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TOIThe Oncology Institute, Inc. Common Stock | D | A | B | $4.78 |
| HIMSHims & Hers Health, Inc. | F | C | C | $27.76 |
| TDOCTeladoc Health, Inc. | B | C | B | $7.91 |
| AIRSAirSculpt Technologies, Inc. Common Stock | F | D | B | $5.30 |
| SBCSBC Medical Group Holdings Incorporated Common Stock | B | F | D | $3.21 |
| LFMDLifeMD, Inc. Common Stock | D | C | C | $4.63 |
| AUNAAuna S.A. | A | D | D | $4.54 |
| BMGLBasel Medical Group Ltd Ordinary Shares | B | B | D | $0.59 |
| CCMConcord Medical Services Holding Limited | B | B | C | $5.00 |
| SBCWWSBC Medical Group Holdings Incorporated Warrants | — | — | C | $0.20 |
| TOIIWThe Oncology Institute, Inc. Warrant | — | — | D | $0.05 |
About
The Oncology Institute Inc operates a diversified oncology platform providing infusion services, specialty pharmacy dispensing, stem cell transplants, clinical trials, and supportive care services. The company generates revenue primarily through its patient services segment, with additional contributions from its proprietary dispensary and clinical trials operations. Its integrated model spans diagnosis, treatment, research, and comprehensive patient support across the oncology care continuum.